NCT03998566 - Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 24, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions

Pancreatic Cancer

Interventions

DEVICE

TraceIT Tissue Spacer implantation

The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.

Trial Locations (3)

21287

Johns Hopkins Medicine, Baltimore

77030

The University of Texas MD Anderson Cancer Center, Houston

02215

Massachusetts General Hospital, Boston